Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses

Hiromichi Ebi, Shuta Tomida, Toshiyuki Takeuchi, Chinatsu Arima, Takahiko Sato, Tetsuya Mitsudomi, Yasushi Yatabe, Hirotaka Osada, Takashi Takahashi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

There is marked disparity with a slight overlap among prognosis-predictive signatures reported thus far for lung cancers. In this study, we aimed at linking poor prognosis with particular pathways and/or functions of the gene sets involved to better understand the underlying molecular characteristics associated with the prognosis of lung adenocarcinomas. Gene set enrichment analysis identified a gene set down-regulated by rapamycin as the most significant, whereas several others responsive to withdrawal of glucose or amino acids, which are related to signaling converging onto mammalian target of rapamycin (mTOR), were also shown to be significantly associated, in addition to those related to DNA damage response and cell cycle progression. We also used connectivity map (C-MAP) analysis, an independent bioinformatics approach, to search for Food and Drug Administration-approved drugs that potentially transform an unfavorable signature to a favorable one. Those results identified inhibitors of phosphatidylinositol 3-kinase (PI3K) and mTOR, as well as unexpected drugs such as phenothiazine antipsychotics and resveratrol as potential candidates. Experimental validation revealed that the latter unexpected agents also inhibited signaling converging onto mTORand exhibited antitumor activities. In addition, deregulation of multiple signaling converging onto mTORwas shown to be significantly associated with sensitivity to PI-103, a dual specificity PI3K/mTORinhibitor that is not contained in the C-MAP database, lending further support for the connection. Our results clearly show the existence of gene set-definable, intrinsic heterogeneities in lung adenocarcinomas, which seem to be related to both clinical behavior and sensitivity to agents affecting the identified pathways.

Original languageEnglish
Pages (from-to)4027-4035
Number of pages9
JournalCancer Research
Volume69
Issue number9
DOIs
Publication statusPublished - May 1 2009
Externally publishedYes

Fingerprint

Sirolimus
Computer Simulation
Phosphatidylinositol 3-Kinase
Genes
United States Food and Drug Administration
Computational Biology
Pharmaceutical Preparations
Antipsychotic Agents
DNA Damage
Lung Neoplasms
Cell Cycle
Databases
Amino Acids
Glucose
Adenocarcinoma of lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. / Ebi, Hiromichi; Tomida, Shuta; Takeuchi, Toshiyuki; Arima, Chinatsu; Sato, Takahiko; Mitsudomi, Tetsuya; Yatabe, Yasushi; Osada, Hirotaka; Takahashi, Takashi.

In: Cancer Research, Vol. 69, No. 9, 01.05.2009, p. 4027-4035.

Research output: Contribution to journalArticle

Ebi, Hiromichi ; Tomida, Shuta ; Takeuchi, Toshiyuki ; Arima, Chinatsu ; Sato, Takahiko ; Mitsudomi, Tetsuya ; Yatabe, Yasushi ; Osada, Hirotaka ; Takahashi, Takashi. / Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. In: Cancer Research. 2009 ; Vol. 69, No. 9. pp. 4027-4035.
@article{22488b30273e4c21a7102537b17e5b41,
title = "Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses",
abstract = "There is marked disparity with a slight overlap among prognosis-predictive signatures reported thus far for lung cancers. In this study, we aimed at linking poor prognosis with particular pathways and/or functions of the gene sets involved to better understand the underlying molecular characteristics associated with the prognosis of lung adenocarcinomas. Gene set enrichment analysis identified a gene set down-regulated by rapamycin as the most significant, whereas several others responsive to withdrawal of glucose or amino acids, which are related to signaling converging onto mammalian target of rapamycin (mTOR), were also shown to be significantly associated, in addition to those related to DNA damage response and cell cycle progression. We also used connectivity map (C-MAP) analysis, an independent bioinformatics approach, to search for Food and Drug Administration-approved drugs that potentially transform an unfavorable signature to a favorable one. Those results identified inhibitors of phosphatidylinositol 3-kinase (PI3K) and mTOR, as well as unexpected drugs such as phenothiazine antipsychotics and resveratrol as potential candidates. Experimental validation revealed that the latter unexpected agents also inhibited signaling converging onto mTORand exhibited antitumor activities. In addition, deregulation of multiple signaling converging onto mTORwas shown to be significantly associated with sensitivity to PI-103, a dual specificity PI3K/mTORinhibitor that is not contained in the C-MAP database, lending further support for the connection. Our results clearly show the existence of gene set-definable, intrinsic heterogeneities in lung adenocarcinomas, which seem to be related to both clinical behavior and sensitivity to agents affecting the identified pathways.",
author = "Hiromichi Ebi and Shuta Tomida and Toshiyuki Takeuchi and Chinatsu Arima and Takahiko Sato and Tetsuya Mitsudomi and Yasushi Yatabe and Hirotaka Osada and Takashi Takahashi",
year = "2009",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-08-3403",
language = "English",
volume = "69",
pages = "4027--4035",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses

AU - Ebi, Hiromichi

AU - Tomida, Shuta

AU - Takeuchi, Toshiyuki

AU - Arima, Chinatsu

AU - Sato, Takahiko

AU - Mitsudomi, Tetsuya

AU - Yatabe, Yasushi

AU - Osada, Hirotaka

AU - Takahashi, Takashi

PY - 2009/5/1

Y1 - 2009/5/1

N2 - There is marked disparity with a slight overlap among prognosis-predictive signatures reported thus far for lung cancers. In this study, we aimed at linking poor prognosis with particular pathways and/or functions of the gene sets involved to better understand the underlying molecular characteristics associated with the prognosis of lung adenocarcinomas. Gene set enrichment analysis identified a gene set down-regulated by rapamycin as the most significant, whereas several others responsive to withdrawal of glucose or amino acids, which are related to signaling converging onto mammalian target of rapamycin (mTOR), were also shown to be significantly associated, in addition to those related to DNA damage response and cell cycle progression. We also used connectivity map (C-MAP) analysis, an independent bioinformatics approach, to search for Food and Drug Administration-approved drugs that potentially transform an unfavorable signature to a favorable one. Those results identified inhibitors of phosphatidylinositol 3-kinase (PI3K) and mTOR, as well as unexpected drugs such as phenothiazine antipsychotics and resveratrol as potential candidates. Experimental validation revealed that the latter unexpected agents also inhibited signaling converging onto mTORand exhibited antitumor activities. In addition, deregulation of multiple signaling converging onto mTORwas shown to be significantly associated with sensitivity to PI-103, a dual specificity PI3K/mTORinhibitor that is not contained in the C-MAP database, lending further support for the connection. Our results clearly show the existence of gene set-definable, intrinsic heterogeneities in lung adenocarcinomas, which seem to be related to both clinical behavior and sensitivity to agents affecting the identified pathways.

AB - There is marked disparity with a slight overlap among prognosis-predictive signatures reported thus far for lung cancers. In this study, we aimed at linking poor prognosis with particular pathways and/or functions of the gene sets involved to better understand the underlying molecular characteristics associated with the prognosis of lung adenocarcinomas. Gene set enrichment analysis identified a gene set down-regulated by rapamycin as the most significant, whereas several others responsive to withdrawal of glucose or amino acids, which are related to signaling converging onto mammalian target of rapamycin (mTOR), were also shown to be significantly associated, in addition to those related to DNA damage response and cell cycle progression. We also used connectivity map (C-MAP) analysis, an independent bioinformatics approach, to search for Food and Drug Administration-approved drugs that potentially transform an unfavorable signature to a favorable one. Those results identified inhibitors of phosphatidylinositol 3-kinase (PI3K) and mTOR, as well as unexpected drugs such as phenothiazine antipsychotics and resveratrol as potential candidates. Experimental validation revealed that the latter unexpected agents also inhibited signaling converging onto mTORand exhibited antitumor activities. In addition, deregulation of multiple signaling converging onto mTORwas shown to be significantly associated with sensitivity to PI-103, a dual specificity PI3K/mTORinhibitor that is not contained in the C-MAP database, lending further support for the connection. Our results clearly show the existence of gene set-definable, intrinsic heterogeneities in lung adenocarcinomas, which seem to be related to both clinical behavior and sensitivity to agents affecting the identified pathways.

UR - http://www.scopus.com/inward/record.url?scp=65949087244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65949087244&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-3403

DO - 10.1158/0008-5472.CAN-08-3403

M3 - Article

C2 - 19383916

AN - SCOPUS:65949087244

VL - 69

SP - 4027

EP - 4035

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 9

ER -